Sometimes the best buying opportunities are when a company is between post-FDA approval and when sales roll in. Usually this is not the case as it takes time for sales to ramp up. Its risky for sure; sales growth from any company is never guaranteed no matter how sound the bull thesis is. When it plays out though, it can be very financially rewarding. A company I have came across recently that has such a value proposition is Evolus (EOLS). EOLS is different from any other company we have covered before in that they are an aesthetics only company . . .